Skip to main content

Table 1 Baseline characteristics of study patients

From: Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study

  Total Events No events p value
  n = 8417 n = 395 n = 8022  
Clinical characteristics
 Age, years 57.4 ± 10.8 62.2 ± 10.2 57.2 ± 10.8  < 0.001
 Male sex, (%) 71.7 71.6 71.7 0.993
 BMI (kg/m2) 25.8 ± 3.2 25.5 ± 3.2 25.9 ± 3.2 0.016
 Hypertension, (%) 62.0 68.8 61.7 0.005
 Dyslipidemia, (%) 74.8 72.3 74.9 0.259
 Diabetes Mellitus, (%) 27.5 37.1 27.0  < 0.001
 Family history of CAD, (%) 13.6 14.3 13.5 0.097
 Current smoker, (%) 54.4 54.3 54.4 0.968
Laboratory findings
 TC (mmol/L) 4.16 ± 1.17 4.17 ± 1.26 4.15 ± 1.17 0.819
 LDL-C (mmol/L) 2.53 ± 1.01 2.53 ± 1.11 2.53 ± 1.00 0.970
 HDL-C (mmol/L) 1.06 ± 0.29 1.05 ± 0.29 1.06 ± 0.29 0.662
 TG (mmol/L) 1.50 (1.10–2.10) 1.48 (1.06–2.10) 1.50 (1.10–2.10) 0.538
 Lipoprotein(a) (mg/dL) 15.18 (6.74–36.79) 19.24(9.01–45.58) 15.00 (6.66–36.26) 0.001
 apoA1 (g/L) 1.33 ± 0.29 1.34 ± 0.30 1.33 ± 0.29 0.726
 apoB (g/L) 0.92 ± 0.30 0.93 ± 0.31 0.92 ± 0.30 0.609
 Fibrinogen(g/L) 3.24 ± 0.79 3.35 ± 0.81 3.23 ± 0.78 0.003
 D-dimer (ug/mL) 0.42 ± 0.62 0.55 ± 0.66 0.42 ± 0.62  < 0.001
Medications at admission
 Statins, (%) 75.5 68.3 75.8 0.005
 Aspirin, (%) 83.6 82.3 83.6 0.557
 ACEI, (%) 12.5 13.3 12.5 0.682
 ARB, (%) 12.8 10.6 12.9 0.361
 β-blockers, (%) 48.2 48.7 48.1 0.893
 CCB, (%) 19.2 15.9 19.3 0.228
Medications at discharge
 Statins, (%) 94.0 95.5 93.9 0.313
 Aspirin, (%) 96.2 96.9 96.2 0.638
 ACEI, (%) 22.2 26.3 22.0 0.096
 ARB, (%) 23.0 26.3 22.9 0.175
 β-blockers, (%) 77.9 80.6 77.8 0.278
 CCB, (%) 38.1 35.3 38.2 0.323
  1. Data are expressed as mean ± SD or median (25–75th percentile) unless otherwise indicated. ACEIs ACE inhibitors; ARBs angiotensin receptor blockers; CCB calcium channel blocker